Gilead Sciences, Inc. (NASDAQ:GILD) Stock Position Lessened by Livforsakringsbolaget Skandia Omsesidigt

Livforsakringsbolaget Skandia Omsesidigt reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 9.2% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 103,737 shares of the biopharmaceutical company’s stock after selling 10,500 shares during the quarter. Gilead Sciences comprises about 0.8% of Livforsakringsbolaget Skandia Omsesidigt’s investment portfolio, making the stock its 25th largest holding. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Gilead Sciences were worth $7,991,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Modus Advisors LLC lifted its position in shares of Gilead Sciences by 9.5% during the 2nd quarter. Modus Advisors LLC now owns 5,646 shares of the biopharmaceutical company’s stock valued at $435,000 after acquiring an additional 491 shares during the last quarter. DGS Capital Management LLC boosted its position in shares of Gilead Sciences by 2.0% in the first quarter. DGS Capital Management LLC now owns 6,570 shares of the biopharmaceutical company’s stock worth $545,000 after buying an additional 131 shares during the period. ORG Partners LLC acquired a new position in Gilead Sciences during the first quarter valued at $5,570,000. ProShare Advisors LLC boosted its position in Gilead Sciences by 9.1% during the 1st quarter. ProShare Advisors LLC now owns 1,331,271 shares of the biopharmaceutical company’s stock worth $110,456,000 after acquiring an additional 111,328 shares during the period. Finally, Empower Advisory Group LLC purchased a new position in Gilead Sciences during the first quarter valued at approximately $648,000. Institutional investors and hedge funds own 82.33% of the company’s stock.

Gilead Sciences Stock Performance

Gilead Sciences stock traded up $0.06 during trading hours on Thursday, hitting $77.37. The stock had a trading volume of 1,029,175 shares, compared to its average volume of 5,756,511. Gilead Sciences, Inc. has a fifty-two week low of $61.44 and a fifty-two week high of $89.74. The company has a market cap of $96.40 billion, a PE ratio of 17.77, a price-to-earnings-growth ratio of 0.83 and a beta of 0.37. The company has a 50-day moving average of $77.23 and a two-hundred day moving average of $78.86. The company has a quick ratio of 0.91, a current ratio of 1.02 and a debt-to-equity ratio of 1.07.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.64 by ($0.30). The business had revenue of $6.60 billion during the quarter, compared to the consensus estimate of $6.45 billion. Gilead Sciences had a net margin of 20.03% and a return on equity of 37.53%. The company’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same period last year, the firm earned $1.58 EPS. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post 6.63 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 28th. Investors of record on Friday, September 15th will be paid a $0.75 dividend. This represents a $3.00 annualized dividend and a yield of 3.88%. The ex-dividend date is Thursday, September 14th. Gilead Sciences’s dividend payout ratio is 68.97%.

Insiders Place Their Bets

In other news, insider Merdad Parsey sold 1,501 shares of the business’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $76.99, for a total value of $115,561.99. Following the sale, the insider now owns 70,130 shares in the company, valued at approximately $5,399,308.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider Merdad Parsey sold 1,501 shares of the business’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $76.99, for a total value of $115,561.99. Following the transaction, the insider now directly owns 70,130 shares of the company’s stock, valued at approximately $5,399,308.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 5,000 shares of the firm’s stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $80.00, for a total value of $400,000.00. Following the sale, the chief financial officer now directly owns 107,587 shares of the company’s stock, valued at $8,606,960. The disclosure for this sale can be found here. Corporate insiders own 0.21% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on GILD. Bank of America raised shares of Gilead Sciences from a “neutral” rating to a “buy” rating and upped their price target for the stock from $88.00 to $95.00 in a research note on Friday, September 8th. BMO Capital Markets dropped their target price on Gilead Sciences from $100.00 to $95.00 in a research report on Tuesday, July 18th. HSBC assumed coverage on shares of Gilead Sciences in a research note on Wednesday, September 6th. They issued a “reduce” rating and a $71.00 target price for the company. Cantor Fitzgerald dropped their price target on shares of Gilead Sciences from $85.00 to $80.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 19th. Finally, Morgan Stanley upped their price objective on shares of Gilead Sciences from $86.00 to $88.00 and gave the stock an “equal weight” rating in a report on Friday, August 4th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $90.05.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis.